CRSP stock: buy or sell
Apr 16th, 2021
CRSP stock brief
- CRISPR Therapeutics stock slightly changed 0.60% to close at $123.85 on the stock market today, after 3 consecutive sessions in green.
- CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases.
Should I buy CRISPR Therapeutics stock?
All successful traders recommend adhering to a trading strategy and not make decisions based on subjective opinions, rumors or feelings. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best
Is $CRSP stock a buy?
In the current situation of CRISPR Therapeutics there is not any eligible buy setup. This doesn't mean we expect a selloff for $CRSP in coming sessions, or that it may not climb higher. Simply, it doesn't match our recommended trading systems
Should I sell CRISPR Therapeutics stock?
How to know when is it time to sell CRISPR Therapeutics stock?. Much like when we have to buy shares, deciding when is appropiate to sell is not a fickle decision, and we must use our own trading style. Our trading system selects very simple strategies to guide us on when is the best time to sell a stock. Be aware that these strategies should not be used for selling short $CRSP stock
As a golden rule, you must never keep a trading operation that shows a higher than expected losses upon purchase. When to sell shares should always be dictated by the stop-loss (automatic or manual)
Is it time to sell CRISPR Therapeutics stock?
Currently, CRISPR Therapeutics stock doesn't match any of our preferred sell setups, so if you hold CRISPR Therapeutics stock and your operation is in profit probably is not time to sell now
CRISPR Therapeutics ratings
We don't have any rating posted in the previous month for CRISPR Therapeutics
CRISPR Therapeutics stock analysis
Supports and resistances
The current resistances are:
The current supports are:
Relative strength index
The RSI crossed up the oversold level of 30 in early March after just being in the oversold zone for a single day (what can be considered a strength signal). The RSI value on Thursday was 50.14. CRISPR Therapeutics stock exploded a 9.00% since RSI left the oversold zone
CRISPR Therapeutics stock price history
CRISPR Therapeutics started trading on Oct 19th, 2016 at $15.00 per share1. Since then, CRSP stock surged by 725.67%, with an average of 181.42% per year. If you had invested thousand dollars in CRISPR Therapeutics stock on Oct 2016, it would have a value of $8,256.67 today.
1: Adjusted price after possible price splits or reverse-splits
Price target for CRISPR Therapeutics stock
Nobody can predict how much a stock will be priced tomorrow. Banks and financial organisations publish their analysis predicting how a stock will performance in the future.
The following table shows the price forecasts published by analysts in the last 30 days. Again, these forecasts are not direct recommendations for individual investors and must not be trusted blindly.
In the previous month we couldn't find any price target published for CRISPR Therapeutics stock.
Earnings and financials
CRISPR Therapeutics AG ($CRSP) released earnings of $-1.50 per share last February, significantly worsening the Market consensus estimate of $-1.27 per share. This quarterly report represents an earnings surprise of -18.11%.Compared to the same quarter last year, EPS was $0.51, so posted EPS means a drop of -394.12%. Looking at revenue, figures sank a -99.52% compared to $770.2M same quarter a year ago.
CRSP ($CRSP) is posting financial report on April 27. Analysts expect of $-1.49, that is a 0.67% higher than Q4.
CRISPR Therapeutics performance
|CRISPR Therapeutics ($CRSP)||-1.80%||-37.10%||19.20%|
Please read:The opinions expressed in this post are personal and not recommendations for you to buy or sell shares. The author of this report does not have any knowledge of the individual positions of the reader, his or her finances or his or her own best interests at any given time. All users should speak with their financial advisor before buying or selling any securities Comments are published for learning purposes only
|Thursday, April 15th, 2021|
|Day range||$121.83 - $126.7|
|Average true range||$8.48|
|50d mov avg||$132.45|
|100d mov avg||$145.89|
|200d mov avg||$118.60|
|Earnings date||April 27th, 2021|